JSJai H. Seth

Jai H. Seth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jai H. Seth has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Arun Sahai

    Guy's and St Thomas' NHS Foundation Trust London UK

    4 shared publications
  • Mahreen Pakzad

    Department of Urology University College Hospital at Westmoreland Street London UK

    4 shared publications
  • Rizwan Hamid

    Department of Urology University College Hospital at Westmoreland Street London UK

    3 shared publications
  • Clare J. Fowler

    Department of Uro‐Neurology National Hospital for Neurology and Neurosurgery UCL Institute of Neurology London UK

    2 shared publications
  • Collette Haslam

    Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, London, UK

    2 shared publications
  • Jalesh N. Panicker

    Department of Uro‐Neurology National Hospital for Neurology and Neurosurgery UCL Institute of Neurology London UK

    2 shared publications

Latest Publications

  • Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy

    by Elsie E. Mensah, Bogdan Toia, Linh Nguyen, Rizwan Hamid, Mahreen Pakzad, Jeremy L. Ockrim, Roger Walker, Tamsin J. Greenwell, Tharani Nitkunan, Davendra Sharma, et al.

    Aims: To determine the bleeding risk in patients taking anticoagulants (AC) and antiplatelets (AP) before onabotulinumtoxinA (BoNT‐A) injections and improve peri‐operative decision making and counseling.Methods: We performed a retrospective review of patients having intravesical BoNT‐A in three teaching hospitals from January 2016 to July 2018. Demographic data, indication for intravesical BoNT‐A injection, and side‐effects of significant bleeding requiring intervention were recorded.Results: Five hundred and thirty‐two patients had intravesical BoNT‐A injections during this time. Sixty‐three patients of mean age 69 years (range 19–89) had a total of 114 separate rounds of BoNT‐A injections whilst on treatment dose AC/AP therapy. Of the 63, there were 33 males, with 46 having idiopatic detrusor overactivity and 17 with neurogenic detrusor overactivity. Each patient had between 1 and 7 repeat injections during the studied period. AC/AP use across the 114 episodes included; aspirin 44, clopidogrel 37, warfarin 19, and NOAC (novel/non‐vitamin K oral anticoagulant) 14. Patients on warfarin who had point of care testing all had international normalized ratio less than 3. BoNT‐A dose varied from 100U to 300U—modal dosage was 200U.1/114(0.88%) injection episodes resulted in postinjection hematuria requiring overnight admission. This resolved spontaneously, with an overnight catheter. This patient was on rivaroxaban and had 300U of BoNT‐A injected through 20 sites, on a background of previous prostate radiotherapy and self‐catheterization.Conclusions: Continuation of AP/AC therapy during intravesical BoNT‐A injection treatment appears to be safe—with a 0.88% rate of spontaneously resolving hematuria.


  • Incidence, type and management of ureteric injury associated with vesicovaginal fistulas: Report of a series from a specialized center

    by Jai Seth, Anthony Kiosoglous, Mahreen Pakzad, Rizwan Hamid, Julian Shah, Jeremy Ockrim, Tamsin Greenwell

    Objectives: To report a large series of vesicovaginal fistula, and to assess the incidence of ureteric injury in association with vesicovaginal fistula.Methods: We retrospectively reviewed a prospective database of patients with vesicovaginal fistula referred to our center between 2004 and 2016. Data on patient demographics, fistula etiology, mode of repair, and any associated ureteric injury and its treatment were noted.Results: Overall, 116 patients (median age 49 years, range 23–88 years) were referred for management of vesicovaginal fistula during the study period. Four of these patients (3.4%) had associated ureteric injury, one of whom had bilateral injury. Ureteric obstruction alone was noted in two patients, ureterovaginal fistula alone in one patient, and bilateral ureteric obstruction and ureterovaginal fistula in one patient. All ureteric injuries were managed with simultaneous reimplantation into the bladder at the time of vesicovaginal fistula repair. Five patients had post‐radiotherapy vesicovaginal fistula, and the remainder were post‐surgical. Three patients with post‐radiotherapy vesicovaginal fistula proceeded to primary diversion.Conclusions: Ureteric injury is far less common than previously reported, occurring in <5% of patients presenting with vesicovaginal fistula. It can be successfully managed, and it remains the major indication for abdominal repair of vesicovaginal fistula.


  • Feasibility of using a novel non-invasive ambulatory tibial nerve stimulation device for the home-based treatment of overactive bladder symptoms

    by Jai H. Seth, Gwen Gonzales, Collette Haslam, Mahreen Pakzad, Arvind Vashisht, Arun Sahai, Charles Knowles, Arthur Tucker, Jalesh Panicker

    Background: To evaluate safety, acceptability and pilot efficacy of transcutaneous low-frequency tibial nerve stimulation (TNS) using a novel device as home-based neuromodulation. Methods: In this single-centre pilot study, 48 patients with overactive bladder (OAB) (24 with neurogenic and 24 with idiopathic OAB) were randomized to use a self-applicating ambulatory skin-adhering device stimulating transcutaneously the tibial nerve at 1 Hz for 30 minutes, either once daily or once weekly, for 12 weeks. Changes in OAB symptoms and QoL were measured at baseline, weeks 4, 8, and 12 using validated scoring instruments (ICIQ-OAB and ICIQ-LUTSqol), 3-day bladder diary and a Global Response Assessment (GRA) at week 12. Results: Thirty-four patients completed the study (idiopathic n=15, neurogenic n=19). No significant adverse effects were noted. Patients found the device acceptable. Eighteen patients (53%) reported a moderate or marked improvement in symptoms from the GRA. Between baseline and week-12, ICIQ-OAB part A sub-scores improved from mean (SD) 9.3 (2.5) to 7.5 (3.1), and from 9.1 (1.9) to 5.9 (1.7) in the daily and the weekly arms, respectively. ICIQ-LUTSqol part A sub-scores improved from mean (SD) 51 (12.8) to 44.2 (13.1) and 44.9 (9.0) to 35.9 (8.8) in the daily and the weekly arms, respectively. Bladder diary mean 24-hour frequency episodes improved from 11.5 to 8.8 at week 12 for both arms. Conclusions: This novel ambulatory transcutaneous TNS (TTNS) device is safe and acceptable for use in patients reporting OAB symptoms as a form of home-based neuromodulation. A larger study however is required to confirm clinical efficacy.


  • Correlation of MRI features of urethral diverticulum and pre‐ and post‐operative stress urinary incontinence

    by Jai H. Seth, Sahar Naaseri, Eskinder Solomon, Mahreen Pakzad, Rizwan Hamid, Jeremy Ockrim, Tamsin J. Greenwell

    Aims: The complexity of urethral diverticulectomy depends on location, size, and degree of circumferential involvement. MRI features were examined to predict functional outcome after surgery for urethral diverticulum (UD).Methods: A prospectively acquired database was of all patients who have had surgical excision of UD at a tertiary center since 2004 was reviewed. Particular focus was pre‐ and post‐operative urodynamically proven stress urinary incontinence (USUI), and pre‐operative MRI features. MRI parameters included diverticular volume, degree of circumferential involvement around the urethra, distance of the Os of UD to bladder neck and urethral length. Students t‐test and Mann‐Whitney U‐test were used to compare rates of de novo USUI.Results: There were 100 patients (mean age 45.8 yrs), who had excision of UD since 2004, with a minimum follow‐up of 10 months (range 10‐112 months). Full MRI data was available for 83 patients. Fourteen were of simple configuration (16.8%), 32 were horseshoe (38.6%), and 37 (44.6%) were circumferential. Twenty‐five (25%) patients had pre‐operative USUI, while 12 (12%) patients developed de novo USUI post‐excision. While, the majority of patients with de novo USUI (67%) had >270° circumferential involvement of urethra, the pre‐operative diverticular volume did not predict the likelihood of USUI developing (P = 0.3). A shorter urethral length was associated with pre‐operative USUI.Conclusions: 25% of all patients had pre‐op USUI, and diverticular volume and urethral length was significantly smaller in this group. The majority of patients with de novo USUI had complex diverticula configuration with higher baseline circumferential angle around urethra, with 67% of angle's between 270 and 360°


  • Case of acute severe postpartum urinary incontinence: an extravesical subsphincteric prolapsed ureterocoele

    by Jai H Seth, Roger Walker

    A 32-year-old woman presents to outpatients 10 days postpartum, with symptoms of an intermittent vaginal lump and urinary incontinence. Vaginal examination revealed no demonstrable prolapse or stress incontinence. A swelling in the bladder was noted during an antenatal scan suggesting a ureterocoele. She was referred for pelvic floor physiotherapy in the first instance. Forty-eight hours later, she represented to casualty with discomforting vaginal lump symptoms and continuous urinary incontinence. At this stage on vaginal inspection, there was an evident dusky lump emerging from the urethra with continuous incontinence. An extravesical subsphincteric prolapsed ureterocoele was evident, 5 cm beyond the external urethral meatus. The diagnosis was confirmed with an MRI scan which demonstrated the prolapsed obstructing ureterocoele causing significant left-sided hydroureteronephrosis. The ureterocoele was managed with a cystoscopy and transurethral incision of the ureterocoele under anaesthesia, which facilitated drainage and resolution. At 3-month postoperatively, the patient remains continent and satisfied.


  • Urethral Sphincter Injection of Botulinum Toxin A: A Review of Its Application and Outcomes

    by Jai Seth, Sophie Rintoul‐Hoad, Arun Sahai

    The first reported application of Botulinum toxin‐A (BTX‐A) into the urethral sphincter predates the first documented use in the bladder. The aim of this review is to describe the clinical indications of BTX‐A injection into the urethral sphincter and its clinical efficacy. This review of the literature includes the larger more significant published studies that have reported on this use of BTX‐A. Case reports and articles not published in English were excluded. There have been many published clinical studies describing the use of BTX‐A in the urethral sphincter, four of which are randomized placebo controlled trials. These studies tend to include patients either in urinary retention or with obstructed voiding, both in the neuropathic and non‐neuropathic populations. Studies tend to demonstrate improvements in urodynamic parameters and quality of life after injection. There have been many small clinical studies in this area, however larger placebo‐controlled trials are needed to evaluate this treatment at higher levels of evidence.


  • Urolithiasis following urinary diversion

    by Jai H. Seth, Joannis Promponas, Marios Hadjipavlou, Faqar Anjum, Seshadri Sriprasad

    Urolithiasis is a well-known occurrence after cystectomy and urinary diversion. With high incidence and recurrence rates of urolithiasis, complex anatomy and associated morbidities, these patients remain a management challenge for urologists. The purpose of this review is to examine the literature and consider the risk factors for stone formation in this group of patients and reflect on the reported outcomes with the range of available treatment options.


  • 878 Licensed and approved vs traditional dose of onabotulinumtoxinA in refractory overactive bladder?

    by D. Eldred-Evans, J. Seth, C. Dowson, S. Malde, J. Watkins, M.S. Khan, P. Dasgupta, A. Sahai

  • Open Access

    Ensuring patient adherence to clean intermittent self-catheterization

    by Jalesh Panicker, Jai Seth, Collette Haslam

    Patient performance of clean intermittent self-catheterization is a crucial component of the management of incomplete bladder emptying, which can arise from a variety of conditions. This allows patients to have more control over their bladder emptying, and avoids the inconveniences that come with an indwelling urethral catheter. There are, however, barriers that patients face when performing this task which may ultimately limit adherence. In this article, these barriers are discussed in more detail with potential solutions to counter them.